Profile data is unavailable for this security.
About the company
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
- Revenue in USD (TTM)0.00
- Net income in USD-766.63m
- Incorporated2013
- Employees507.00
- LocationVaxcyte Inc825 INDUSTRIAL ROAD, STE. 300SAN CARLOS 94070United StatesUSA
- Phone+1 (650) 837-0111
- Fax+1 (302) 655-5049
- Websitehttps://vaxcyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.66bn | 25.00 | -- | -- | -- | -- | -1.55 | -1.55 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Arcellx Inc | 22.29m | -228.93m | 6.67bn | 209.00 | -- | 16.42 | -- | 299.27 | -4.06 | -4.06 | 0.3945 | 6.95 | 0.0339 | -- | 7.31 | 106,631.60 | -34.81 | -28.60 | -42.17 | -34.05 | -- | -- | -1,027.26 | -274.64 | -- | -- | 0.00 | -- | -79.35 | -- | -113.26 | -- | 21.25 | -- |
| Kymera Therapeutics Inc | 39.21m | -311.35m | 7.36bn | 238.00 | -- | 4.64 | -- | 187.60 | -3.68 | -3.68 | 0.4642 | 19.42 | 0.0288 | -- | -- | 164,747.90 | -22.89 | -24.17 | -24.23 | -27.06 | -- | -- | -794.06 | -329.38 | -- | -- | 0.0021 | -- | -16.70 | 2.87 | -39.08 | -- | -30.75 | -- |
| Cytokinetics, Inc. | 88.04m | -784.96m | 7.57bn | 673.00 | -- | -- | -- | 85.94 | -6.53 | -6.53 | 0.733 | -5.37 | 0.0623 | -- | 5.12 | 130,815.80 | -55.55 | -49.49 | -64.23 | -55.60 | -- | -- | -891.60 | -897.66 | -- | -11.95 | 2.33 | -- | 376.56 | 9.54 | -33.15 | -- | 17.55 | -- |
| Nuvalent Inc | 0.00 | -425.38m | 7.96bn | 228.00 | -- | 6.35 | -- | -- | -5.85 | -5.85 | 0.00 | 15.96 | 0.00 | -- | -- | 0.00 | -33.30 | -27.97 | -35.31 | -29.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.13 | -- | -- | -- |
| ICON PLC | 8.10bn | 599.48m | 8.27bn | 39.80k | 14.64 | 0.8857 | 8.37 | 1.02 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -144.34m | 8.79bn | 18.30k | -- | 2.78 | 33.67 | 2.19 | -2.96 | -2.96 | 80.79 | 64.30 | 0.5477 | 9.04 | 5.62 | 219,419.80 | -1.94 | 3.42 | -2.28 | 4.01 | 34.98 | 36.22 | -3.54 | 6.37 | 1.02 | 3.43 | 0.3999 | 0.00 | -0.8545 | 6.55 | -1,501.75 | -- | 5.64 | -- |
| Vaxcyte Inc | 0.00 | -766.63m | 8.92bn | 507.00 | -- | 3.02 | -- | -- | -5.63 | -5.63 | 0.00 | 20.49 | 0.00 | -- | -- | 0.00 | -23.54 | -24.62 | -24.86 | -26.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -65.25 | -- | 118.08 | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 9.01bn | 711.00 | 41.75 | 15.55 | 34.82 | 8.26 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.05bn | 3.10k | 113.92 | 4.48 | 49.24 | 7.44 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Praxis Precision Medicines Inc | 0.00 | -303.27m | 9.21bn | 168.00 | -- | 9.49 | -- | -- | -13.45 | -13.45 | 0.00 | 34.85 | 0.00 | -- | -- | 0.00 | -42.68 | -61.92 | -45.82 | -68.99 | -- | -- | -- | -9,004.13 | -- | -- | 0.00 | -- | -100.00 | -- | -65.88 | -- | -- | -- |
| Tempus AI Inc | 1.27bn | -245.03m | 9.53bn | 3.80k | -- | 19.34 | -- | 7.49 | -1.41 | -1.41 | 7.30 | 2.76 | 0.7946 | 10.52 | 5.46 | 334,681.30 | -15.31 | -41.14 | -19.31 | -55.06 | 62.74 | 54.59 | -19.27 | -55.73 | 3.00 | -3.90 | 0.7161 | -- | 83.41 | 46.57 | 67.17 | -- | 15.24 | -- |
| Madrigal Pharmaceuticals Inc | 958.40m | -288.28m | 9.99bn | 915.00 | -- | 16.51 | -- | 10.43 | -12.85 | -12.85 | 42.72 | 26.39 | 0.8327 | 1.03 | 10.18 | 1,047,435.00 | -25.05 | -53.85 | -31.64 | -68.43 | 94.14 | -- | -30.08 | -146.24 | 3.77 | -- | 0.3606 | -- | 432.05 | -- | 38.12 | -- | 59.68 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 10.66bn | 1.08k | 14.74 | 4.98 | 13.13 | 4.59 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Immunitybio Inc | 113.29m | -351.40m | 10.73bn | 691.00 | -- | -- | -- | 94.75 | -0.3898 | -0.3898 | 0.1232 | -0.4946 | 0.2561 | 0.164 | 5.04 | 163,947.90 | -79.44 | -101.72 | -91.74 | -204.78 | 99.34 | -- | -310.25 | -1,629.94 | 5.08 | -1.75 | 2.64 | -- | 668.31 | 184.76 | 15.03 | -- | 20.57 | -- |
Data as of Mar 02 2026. Currency figures normalised to Vaxcyte Inc's reporting currency: US Dollar USD
65.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 13.23m | 10.11% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 11.30m | 8.63% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 11.30m | 8.63% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.26m | 8.60% |
| RA Capital Management LPas of 31 Dec 2025 | 10.72m | 8.19% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 8.69m | 6.64% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 5.66m | 4.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.98m | 3.80% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2025 | 4.07m | 3.11% |
| Deep Track Capital LPas of 31 Dec 2025 | 4.00m | 3.06% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
